Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.

Alcoholism, clinical and experimental research - 1 Mar 2009

Oroszi Gabor, Anton Raymond F, O'Malley Stephanie, Swift Robert, Pettinati Helen, Couper David, Yuan Qiaoping, Goldman David

Abstract excerpt

BACKGROUND: Individualized pharmacotherapy requires identification of genetic variants predictive of treatment response. In OPRM1, Asn40Asp has been reported to be predictive of response to naltrexone treatment. Nevertheless, the in vitro function of the polymorphism remains elusive and over 300 OPRM1 sequence variants have been identified to date. Therefore we used a haplotype-based approach to capture...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Amino Acid Substitution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Haplotypes

Share to Naltrexone

Share to Narcotic Antagonists

Share to Receptors, Opioid, mu

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 19053977
DOI: 10.1111/j.1530-0277.2008.00846.x
PMCID: PMC2679376

Genes

OPRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.PMID 19053977Read ↗

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.Semantic proximity Read ↗

Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.Semantic proximity Read ↗

Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.Semantic proximity Read ↗

Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.Semantic proximity Read ↗

Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.Semantic proximity Read ↗

Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.Semantic proximity Read ↗

Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.Semantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans.Semantic proximity Read ↗

Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.Semantic proximity Read ↗

Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.Semantic proximity Read ↗

Pharmacogenetics of alcohol and alcohol dependence treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.